Launching the production of tests for the identification of AMR in the MIC (Q104369): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item)
(‎Removed claim: summary (P836): The objectives of the project are: And//commercialisation of the R & D work carried out by Bioxima S.A. and the Marie Curie University by launching the production of new products: testing for the identification of the MIC (AMR). II/increase in the Company’s competitiveness on the domestic and foreign markets. III/acquisition of new market outlets for the business (Poland — new counterparties and Romania — promising future market for new produc...)
Property / summary
The objectives of the project are: And//commercialisation of the R & D work carried out by Bioxima S.A. and the Marie Curie University by launching the production of new products: testing for the identification of the MIC (AMR). II/increase in the Company’s competitiveness on the domestic and foreign markets. III/acquisition of new market outlets for the business (Poland — new counterparties and Romania — promising future market for new products). IV/an increase in revenues and profits for future research projects and their commercialisation. VI/creation of new jobs in an innovative Polish biotechnology company. In order to achieve the above objectives, the Company will purchase the fixed assets necessary for production. The launch of production in/in production and the introduction to the general public in the microbiological diagnosis of the MIC test will favour the rational supplementation of antibiotics and thus restrict their use. So far, there is no producer in Poland to test the minimum inhibitory concentration and there are only a few in the world. On the basis of data from the European Centre for Prevention and Control of Infections, some 25 patients die each year from infections caused by bacteria resistant to all available antibiotics in the EU. Recent data confirm that the number of patients with resistant bacteria is increasing throughout the EU and that antibiotic resistance is a serious threat to public health. The rational use of antibiotics may help to inhibit the development of resistant bacteria and preserve the efficiency of the use of antibiotics for future generations. An antibiotic therapy based on a MIC study is a reduction in treatment time, a reduction in complications, a reduction in the length of incapacity for work. A targeted therapy, based on a qualitative (anti-biogram) and quantitative analysis (MIC), increases the likelihood of a therapeutic success. In addition to economic effects, it is also the objective of the Applicant’s activities. (English)
 
Property / summary: The objectives of the project are: And//commercialisation of the R & D work carried out by Bioxima S.A. and the Marie Curie University by launching the production of new products: testing for the identification of the MIC (AMR). II/increase in the Company’s competitiveness on the domestic and foreign markets. III/acquisition of new market outlets for the business (Poland — new counterparties and Romania — promising future market for new products). IV/an increase in revenues and profits for future research projects and their commercialisation. VI/creation of new jobs in an innovative Polish biotechnology company. In order to achieve the above objectives, the Company will purchase the fixed assets necessary for production. The launch of production in/in production and the introduction to the general public in the microbiological diagnosis of the MIC test will favour the rational supplementation of antibiotics and thus restrict their use. So far, there is no producer in Poland to test the minimum inhibitory concentration and there are only a few in the world. On the basis of data from the European Centre for Prevention and Control of Infections, some 25 patients die each year from infections caused by bacteria resistant to all available antibiotics in the EU. Recent data confirm that the number of patients with resistant bacteria is increasing throughout the EU and that antibiotic resistance is a serious threat to public health. The rational use of antibiotics may help to inhibit the development of resistant bacteria and preserve the efficiency of the use of antibiotics for future generations. An antibiotic therapy based on a MIC study is a reduction in treatment time, a reduction in complications, a reduction in the length of incapacity for work. A targeted therapy, based on a qualitative (anti-biogram) and quantitative analysis (MIC), increases the likelihood of a therapeutic success. In addition to economic effects, it is also the objective of the Applicant’s activities. (English) / rank
Normal rank
 

Revision as of 17:02, 17 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
Launching the production of tests for the identification of AMR in the MIC
Project in Poland financed by DG Regio

    Statements

    country
    Poland
    0 references
    EU contribution
    589,200.0 zloty
    0 references
    141,408.0 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    budget
    982,000.0 zloty
    0 references
    235,680.0 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    co-financing rate
    60.0 percent
    0 references
    start time
    1 September 2019
    0 references
    end time
    31 December 2021
    0 references
    beneficiary name (string)
    BIOMAXIMA SPÓŁKA AKCYJNA
    0 references
    beneficiary
    Q2511362
    0 references
    summary
    Cele projektu to: I/ komercjalizacja prac badawczo - rozwojowych przeprowadzonych przez Biomaxima S.A. oraz Uniwersytet Marii Curie - Skłodowskiej poprzez uruchomienie produkcji nowych produktów: testów do oznaczania lekooporności MIC. II/ wzrost konkurencyjności Spółki na rynku krajowym i zagranicznym. III/ pozyskanie nowych dla przedsiębiorstwa rynków zbytu (Polska - nowi kontrahenci oraz Rumunia - perspektywiczny rynek zbytu dla nowych produktów). IV/ wzrost przychodów i zysków, które zostaną przeznaczone na kolejne projekty badawcze oraz ich komercjalizację. VI/ utworzenie nowych stanowisk pracy w innowacyjnej polskiej firmie biotechnologicznej. Aby zrealizować powyższe cele Spółka zakupi środki trwałe niezbędne do działalności produkcyjnej. Uruchomienie w/w produkcji i wprowadzenie do powszechnego stosowania w diagnostyce mikrobiologicznej testów MIC będzie sprzyjało racjonalnej suplementacji antybiotyków, a tym samym ograniczeniu ich stosowania. Do tej pory nie ma w Polsce producenta testów do oznaczania minimalnego stężenia hamującego, a na świecie jest ich tylko kilku. Na podstawie danych Europejskiego Centrum Profilaktyki i Kontroli Zakażeń z powodu zakażeń wywoływanych przez bakterie oporne na wszystkie dostępne antybiotyki w UE umiera co roku około 25 tys. pacjentów. Najnowsze dane potwierdzają, że w całej UE wzrasta liczba pacjentów zakażonych bakteriami opornymi i że antybiotykooporność jest poważnym zagrożeniem dla zdrowia publicznego. Racjonalne stosowanie antybiotyków może przyczynić się do zahamowania rozwoju bakterii opornych i zachowania skuteczności stosowania antybiotyków dla przyszłych pokoleń. Celowana antybiotykoterapia w oparciu o badanie MIC to skrócenie czasu leczenia, zmniejszenie liczby powikłań, skrócenie czasu niezdolności do pracy. Terapia celowana, oparta o analizę jakościową (antybiogram) i ilościową (MIC) zwiększa prawdopodobieństwo sukcesu terapeutycznego. Prócz efektów ekonomicznych, to również cel działań Wnioskodawcy. (Polish)
    0 references

    Identifiers

    Polish Kohesio ID
    RPLU.03.07.00-06-0070/19
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q104369&oldid=6431266"